Telitacicept
- Generic Name
- Telitacicept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2136630-26-5
- Unique Ingredient Identifier
- 1FHM3D7Z49
- Indication
用于治疗系统性红斑狼疮（SLE）、类风湿性关节炎等多种自身免疫疾病。
小知识：SLE症状表现多样，如面部出现红斑、关节肿痛、对光过敏、口腔溃疡等，随着病情的进展可导致肾脏、心血管等全身多系统、多器官的不可逆损害，严重威胁生命。目前，我国SLE患病人数超过100万，居全球之首，且多发于15-45岁的年轻女性，女性患病率为男性的10.1倍。
- Associated Conditions
- -
- Associated Therapies
- -
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 30
- Registration Number
- NCT06723548
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-09-26
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 172
- Registration Number
- NCT06614985
- Locations
- 🇨🇳
Renmin Hospital of Wuhan university, Wuhan, Hubei China, China
The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06546540
- Locations
- 🇨🇳
Peking Third Hospital, Beijing, China
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06456567
- Locations
- 🇺🇸
Hemet site, Hemet, California, United States
🇺🇸Menifee site, Menifee, California, United States
🇺🇸Rockford site, Rockford, Illinois, United States
Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 38
- Registration Number
- NCT06375005
- Locations
- 🇨🇳
Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
🇨🇳Huashan Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Effect of Telitacicept on Antibody Titers in Primary APS Patients
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06315530
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2024-08-21
- Target Recruit Count
- 20
- Registration Number
- NCT06125405
- Locations
- 🇨🇳
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 296
- Registration Number
- NCT05998759
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical College, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT05965284
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 40
- Registration Number
- NCT05962840
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.